Topics
lung cancerDisease
Immune checkpointProtein
DurvalumabChemical substance
chemotherapyTelevision station
etoposideChemical substance
PD-L1Biomolecule
Immune checkpoint blockade targeting the PD-1/PD-L1 pathway in combination with platinum-based chemotherapy (CT) has demonstrated improved clinical outcomes in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab ± Tremelimumab in combination with etoposide and platinum-based CT (EP) as first-line treatment for pts with ES-SCLC. Results will be presented at WCLC 2019 including OS, key secondary endpoints, safety and tolerability
Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
Altres ajuts: Roche.Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventiona...
AbstractAnti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1) monotherapies h...
Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus...
Background: Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at present...
Importance: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monothe...
Objectives In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination wi...
BACKGROUND: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-s...
INTRODUCTION: S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating th...
Background: The phase 3 MYSTIC study of durvalumab ± tremelimumab versus chemotherapy in metastatic ...
BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall sur...
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lu...
Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in...
Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
Altres ajuts: Roche.Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventiona...
AbstractAnti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1) monotherapies h...
Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus...
Background: Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at present...
Importance: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monothe...
Objectives In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination wi...
BACKGROUND: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-s...
INTRODUCTION: S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating th...
Background: The phase 3 MYSTIC study of durvalumab ± tremelimumab versus chemotherapy in metastatic ...
BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall sur...
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lu...
Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in...
Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) pro...
Altres ajuts: Roche.Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventiona...
Add to ORKG